Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Mutations in FMS-like tyrosine kinase 3 (FLT3), such as internal tandem duplications (ITDs), can be found in up to 23% of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Current treatment options for FLT3(ITD)-positive AMLs include genotoxic therapy and FLT3 inhibitors (FLT3i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Maifrede, Silvia, Nieborowska-Skorska, Margaret, Sullivan-Reed, Katherine, Dasgupta, Yashodhara, Podszywalow-Bartnicka, Paulina, Le, Bac Viet, Solecka, Martyna, Lian, Zhaorui, Belyaeva, Elizaveta A., Nersesyan, Alina, Machnicki, Marcin M., Toma, Monika, Chatain, Nicolas, Rydzanicz, Malgorzata, Zhao, Huaqing, Jelinek, Jaroslav, Piwocka, Katarzyna, Sliwinski, Tomasz, Stoklosa, Tomasz, Ploski, Rafal, Fischer, Thomas, Sykes, Stephen M., Koschmieder, Steffen, Bullinger, Lars, Valent, Peter, Wasik, Mariusz A., Huang, Jian, Skorski, Tomasz
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034642/
https://ncbi.nlm.nih.gov/pubmed/29784639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-834895
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados